Bemcentinib (R428)
Modify Date: 2024-01-01 18:59:31
Bemcentinib (R428) structure
|
Common Name | Bemcentinib (R428) | ||
|---|---|---|---|---|
| CAS Number | 1037624-75-1 | Molecular Weight | 506.645 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 799.6±70.0 °C at 760 mmHg | |
| Molecular Formula | C30H34N8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 437.4±35.7 °C | |
Use of Bemcentinib (R428)Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM. |
| Name | 1-(6,7-dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine |
|---|---|
| Synonym | More Synonyms |
| Description | Bemcentinib (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 14 nM (Axl kinase) |
| In Vitro | Bemcentinib (R428) (2μM) significantly interferes with mechanisms of migration and invasion of Axlpos melanoma cells at levels comparable to Axl knockdown[1]. Bemcentinib (R428) synergizes with cisplatin to enhance suppression of liver micrometastasis[2]. Bemcentinib (R428) (50 nM-1μM) causes a concentration-dependent inhibition of preadipocyte differentiation into mature adipocytes, as evidenced by reduced lipid uptake[3]. |
| In Vivo | Bemcentinib (R428) (125 mg/kg, p.o.) significantly blocks MDA-MB-231-luc-D3H2LN metastases development in two independent mouse models of breast cancer dissemination, suppresses both tumor angiogenesis and vascular endothelial growth factor (VEGF)-induced corneal neovascularization in vivo[2]. Bemcentinib (R428) (75 mg/kg/day, 25 mg/kg twice daily, p.o.) makes mice keep on a high-fat diet resulted in significantly reduced weight gain and subcutaneous and gonadal fat mass[3]. |
| Cell Assay | Cells maintained for 24 hours in serum-free medium are harvested and transferred to the upper chamber (1.5×105 cells per well) of uncoated (migration) or matrigel-coated (invasion) 24-well chambers. RPMI medium containing 10% fetal bovine serum is added to the lower chamber. Bemcentinib (R428) (2 μM) or vehicle (DMSO, 0.25%) is added for 2 hours to cells before loading them in the upper chambers. Both the upper and lower chambers contain the drug or vehicle. Quantification of migrating/invading cells is obtained by measuring their fluorescent signals with a 480/520 nm filter set on an Infinite M1000 microplate reader 20 or 42 hours later, respectively. |
| Animal Admin | Seven- to 8-wk-old female NCr nu/nu mice are injected intracardially with bioluminescent MDA-MB-231-luc-D3H2LN cell suspension. Oral dosing with Bemcentinib (R428) (125 mg/kg, p.o.) or vehicle twice daily begins 2 h before cell implantation and continue to day 21 (n=20). Metastatic burden is quantified by in vivo bioluminescence imaging on day 22 and analyzed using the Wilcoxon rank sum test. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 799.6±70.0 °C at 760 mmHg |
| Molecular Formula | C30H34N8 |
| Molecular Weight | 506.645 |
| Flash Point | 437.4±35.7 °C |
| Exact Mass | 506.290649 |
| PSA | 98.51000 |
| LogP | 4.55 |
| Vapour Pressure | 0.0±2.8 mmHg at 25°C |
| Index of Refraction | 1.768 |
| Storage condition | -20℃ |
| Water Solubility | Insuluble (5.6E-5 g/L) (25 ºC) |
| 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N-[(7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl]- |
| 1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N-[(7S)-7-(1-pyrrolidinyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl]-1H-1,2,4-triazole-3,5-diamine |
| CS-1046 |
| R428 |
| 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(S)-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine |
| BGB324 |
| BGB-324 |